Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3539-3548

  Bello, Lorenzo ^a   Giussani, Carlo ^a   Carrabba, Giorgio ^a   Pluderi, Mauro ^a   Lucini, Valeria ^a   Pannacci, Marilou ^a   Caronzolo, Dario ^a   Tomei, Giustino ^a   Villani, Roberto ^a   Scaglione, Francesco ^a   Carroll, Rona S ^c   Bikfalvi, Andreas ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b INSERM   (France)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; RECOMBINANT PROTEIN; THROMBOCYTE FACTOR 4; CARBOPLATIN; ETOPOSIDE; METALLOPROTEINASE; RECOMBINANT PROTEIN PEX; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; CHEMISTRY; DISEASE MODEL; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; RECURRENT DISEASE; TIME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN CELL; LOW DRUG DOSE; MICROSURGERY; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PLATELET FACTOR 4; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; RECURRENCE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036847733     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Nicholas, M. K., Prados, M. D., and Larson, D. A. Malignant astrocytomas. In: P. M. Black and J. Loeffier (eds.), Cancer of the Nervous System, pp. 464-491. Blackwell, London 1997
2. Nieder, C., Grosu, A. L., and Molls, M. A comparison of treatment for recurrent malignant gliomas. Cancer Treat Rev., 26: 397-409, 2000
3. Bjerkvig, R, Lund-Johansen, M., and Edvarsen, K. Tumor cell invasion and angiogenesis in the central nervous system. Curr. Opin. Oncol., 9: 223-229, 1997
4. Giese, A., and Westphal, M. Glioma invasion in the central nervous system. Neurosurgery, 39: 235-252, 1996
5. Kappelle, A. C., Postma, T. J., Taphoorn, M. J., Vanderbent, M. J., Van Groeningen, C. J., Sneeuw, K. C., and Heimans, J. J. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology, 56: 118-120, 2001
6. Levin, V. A. Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading. Neuro-Oncol. 1: 69-80, 1999
7. Brandes, A. A., Ermani, M., Basso, U., Amista, P., Berti, F., Scienza, R., Rotilio, A., Pinna, G., Gardiman, M., and Monfardini, S. Temozolomide as a second-line systemic regimen in recurrent high-grade: a phase II study. Ann. Oncol., 12: 255-257, 2001
8. Brooks, P. C. Role of integrins in angiogenesis. Eur. J. Cancer, 14: 2423-2429, 1996
9. Hanahan, D., and Folkman, J. Patterns and Emerging Mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1997
10. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell, 64: 327-336, 1997
11. Nguyen, J. T., Wu, P., Clouse, M. E., Hlatky, L., and Terwillinger, E. F. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res., 58: 5673-5677, 1998
12. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997
13. Tanaka, T., Manome, Y., Wen, P., Kufe, D. W., and Fine, H. A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med., 3: 437-442, 1997
14. Kirsch, M., Strasser, J., Allende, R., Bello, L., Zhang, J., and Black, P. M. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res., 58: 4654-4659, 1998
15. Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N. T., Dunn, I. F., Abe, T., Carroll, R. S., and Black, P. M. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol., 19: 35-39, 2001
16. Chopra, R., and Mikkelsen, T. Experimental animal models for the study of brain tumors. In: T. Mikkelsen, R. Bjerkvig, O. D. Laerum, and M. L. Rosemblum (eds.), Brain Tumor Invasion: Biological, Clinical and Therapeutic Considerations, pp. 231-250. New York 1998
17. Bello, L., Lucini, V., Carrabba, G., Giussani, C., Machluf, M., Pluderi, M., Nikas, D., Zhang, J. P, Tomei, G., Villani, R., Carroll, R. S., Bikfalvi, A., and Black, P. M. Simultaneous inhibition of glioma angiogenesis, cell proliferation and migration by a naturally occurring fragment of human MMP-2. Cancer Res., 61: 8370-8376, 2001
18. Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F., Scaglione, F., Landrè, J., Tomei, G., Villani, R., Carroll, R. S., Black, P. M., and Bikfalvi, A. Low dose chemotherapy combined with an anti angiogenic drug reduces human glioma growth in vivo. Cancer Res., 61: 7501-7506, 2001
19. Joaun, V., Canron, X., Alemany, M., Caen, J. P., Quentin, G., Plouet, J., and Bikfalvi, A. Inhibition of angiogenesis of platelet factor-4 derived peptides and mechanism of action. Blood, 94: 984-993, 1999
20. Hagedorn M., Zilberberg, L., Lozano, R. M., Cuevas, P., Canron, X., Redondo-Horcajo, M., Gimenez-Gallego, G., and Bikfalvi, A. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J., 10: 1096, 2001
21. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig., 105: 1-17, 2000
22. Klement, G:, Huang, P., Mayer, B., Green, S. K., Man, S., Bohlen, P., Hicklin, D., and Kerbel, R. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res., 8: 221-232, 2002
23. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000
24. Marchetti, F., Bishop, J. B., Lowe, X., Generoso, W. M., Hozier, J., and Wyrobek, A. J. Etoposide induces heritable chromosomal aberrations and aneuploidy during male meiosis in the mouse. Proc. Natl. Acad. Sci. USA, 98: 3952-3957, 2001
25. Sato, Y., Kashimoto, S., Mc Donald, J. R., and Nokako, R. In vivo antitumor efficacy of MGI-114 in various human tumor xenograft models including several lung and gastric tumors. Eur. J. Cancer, 37: 1418-1428, 2001
26. Yang, M., Baranov, E., Wang, J-W., Jiang, P., Wang, X., Sun, F-X., Bouvet, M., Moossa, A. R., Penman, S., and Hoffman, M. R. Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proc. Natl. Acad. Sci. USA, 99: 3824-3829, 2002
27. Alessandro, R., Savage, S. A., Mikkelsen, T., and Kohn, E. C. Invasion and angiogenesis: Translational therapeutic strategies. In: T. Mikkelsen, R. Bjerkvig, O. D. Laerum, and M. L. Rosemblum (eds.), Brain Tumor Invasion: Biological, Clinical and Therapeutic Considerations, pp. 415-434. New York, 1998
28. Mareel, M., Dierckx, R., and De Neve, W. Anti-invasive brain tumor therapies. In: T. Mikkelsen, R. Bjerkvig, O. D. Laerum, and M. L. Rosemblum (eds.), Brain Tumor Invasion: Biological, Clinical and Therapeutic Considerations, pp. 391-414. New York, 1998
29. Kakeji, Y., and Teicher, B. A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Investig. New Drugs, 15: 39-48, 1997
30. Rashidi, B., An, Z., Sun, FX., Li. X., Tang, Z. Y., Moosa, A. R., and Hoffman, R. M. Efficacy of intra-hepatectomy 5-FU on recurrence and metastasis of human hepatocellular carcinoma in nude mice. Int. J. Cancer, 15: 231-235, 2001
31. Brooks, P. C., Silletti, S., von Schalcha, T. L., Friedlander, M., and Cheresh, D. A. Disruption of angiogenesis by PEX, a non catalytic metalloproteinase fragment with integrin binding activity. Cell, 92: 391-400, 1998
32. Peifer, A., Kessler, T., Silletti, S., Cheresh, D. A., and Verna, I. M. Suppression of angiogenesis by lentiviral delivery of PEX, a non catalytic fragment of matrix metalloproteinases 2. Proc. Natl. Acad. Sci. USA, 97: 12222-12232, 2000
33. Hanahan, D., Bergers, G., and Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Investig., 105: 1045-1047, 2000